ClearPoint Neuro, Inc. Files Definitive Proxy Statement

TL;DR

<b>ClearPoint Neuro, Inc. has filed its Definitive Proxy Statement for the fiscal year ending December 31, 2023, detailing executive compensation and historical company information.</b>

AI Summary

ClearPoint Neuro, Inc. (CLPT) filed a Proxy Statement (DEF 14A) with the SEC on April 5, 2024. ClearPoint Neuro, Inc. (CLPT) filed a Definitive Proxy Statement (DEF 14A) on April 5, 2024. The filing covers the fiscal year ending December 31, 2023. The company was formerly known as MRI Interventions, Inc. and Surgivision Inc. The filing includes data related to executive compensation, specifically the fair value of equity awards granted, outstanding, unvested, and vested. Data is presented for the fiscal years 2021, 2022, and 2023.

Why It Matters

For investors and stakeholders tracking ClearPoint Neuro, Inc., this filing contains several important signals. This DEF 14A filing provides shareholders with crucial information regarding executive compensation practices and the company's governance, enabling informed voting decisions. The historical company name changes and SIC code provide context for the company's evolution and its position within the medical device industry.

Risk Assessment

Risk Level: low — ClearPoint Neuro, Inc. shows low risk based on this filing. The filing is a routine DEF 14A, which is standard for public companies and does not indicate any unusual financial or operational events.

Analyst Insight

Review the executive compensation details and any shareholder proposals to make informed voting decisions.

Key Numbers

• 2023-12-31 — Fiscal Year End (Reporting period)
• 2024-04-05 — Filing Date (Date of submission)
• DEF 14A — Form Type (Type of filing)
• 001-34822 — SEC File Number (Company's SEC file number)

Key Players & Entities

• ClearPoint Neuro, Inc. (company) — Filer name
• CLPT (company) — Ticker symbol
• DEF 14A (document) — Filing type
• 2024-04-05 (date) — Filing date
• 2023-12-31 (date) — Fiscal year end
• MRI Interventions, Inc. (company) — Former company name
• Surgivision Inc (company) — Former company name
• Solana Beach, CA (location) — Business address

FAQ

Industry Context

ClearPoint Neuro operates in the surgical and medical instruments & apparatus industry, focusing on neurosurgery.

Regulatory Implications

The filing is a DEF 14A, a standard disclosure document required by the SEC for public companies soliciting proxies from shareholders.

What Investors Should Do

1. Analyze the executive compensation tables for changes in equity awards and total compensation.
2. Review any shareholder proposals and management's recommendations.
3. Note the historical company name changes for context on corporate evolution.

Key Dates

• 2024-04-05: Filing Date — Submission of Definitive Proxy Statement
• 2023-12-31: Fiscal Year End — Period covered by the filing

Year-Over-Year Comparison

This filing is a DEF 14A, which is a routine disclosure. No specific comparative data from a prior filing was provided in the text.

Key Financial Figures

• $9,000 — tion of proxies for an estimated fee of $9,000 plus expenses. Morrow Sodali may conduc

Filing Documents

• clpt-20240404.htm (DEF 14A) — 721KB
• clpt-20240404_g1.jpg (GRAPHIC) — 6KB
• clpt-20240404_g2.jpg (GRAPHIC) — 5KB
• clpt-20240404_g3.jpg (GRAPHIC) — 165KB
• clpt-20240404_g4.jpg (GRAPHIC) — 179KB
• clpt-20240404_g5.jpg (GRAPHIC) — 161KB
• 0001285550-24-000045.txt (&nbsp;) — 2583KB
• clpt-20240404.xsd (EX-101.SCH) — 4KB
• clpt-20240404_def.xml (EX-101.DEF) — 6KB
• clpt-20240404_lab.xml (EX-101.LAB) — 8KB
• clpt-20240404_pre.xml (EX-101.PRE) — 5KB
• clpt-20240404_htm.xml (XML) — 93KB

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 29 EQUITY COMPENSATION PLAN INFORMATION 33 BENEFIT PLANS 37 CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS 39

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 40 STOCKHOLDER PROPOSALS FOR 202 5 ANNUAL MEETING 41 ANNUAL REPORT AND FINANCIAL INFORMATION 42 OTHER BUSINESS 43 APPENDIX A A-1 ClearPoint Neuro, Inc. 120 S. Sierra Avenue, Suite 100 Solana Beach, California 92075 Proxy Statement for Annual Meeting of Stockholders IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE STOCKHOLDERS MEETING TO BE HELD ON WEDNESDAY, MAY 15, 2024: THIS PROXY STATEMENT, THE PROXY CARD AND OUR 2023 ANNUAL REPORT ON FORM 10-K ARE AVAILABLE ON THE INTERNET AT HTTPS://WWW.CSTPROXY.COM/CLEARPOINTNEURO/2024. GENERAL INFORMATION What is the Notice of Internet Availability of Proxy Materials and why am I receiving it? Pursuant to the "e-proxy" rules promulgated by the Securities and Exchange Commission (the "SEC"), we are providing access to our proxy materials in a fast and efficient manner via the Internet. Accordingly, on or about April 5, 2024, we mailed a Notice of Internet Availability of Proxy Materials (the "Notice") to all stockholders of record as of the close of business on March 18, 2024, and posted our proxy materials on the website referenced in the Notice (https://www.cstproxy.com/clearpointneuro/2024). As more fully described in the Notice, all stockholders may choose to access our proxy materials on the website referred to in the Notice. The Notice contains instructions on how to access and read this Proxy Statement and our Annual Report on the Internet and how to vote online. If you received a Notice by mail, you will not receive paper copies of the proxy materials in the mail, unless you request them. If you received a Notice by mail and would like to receive a printed copy of the materials, please follow the instructions on the Notice for requesting the materials, and we will promptly mail the materials to you. What is this document? This document is the Proxy Statement of ClearPoint Neuro, Inc. for the 2024 Annual Me

View Full Filing

View this DEF 14A filing on SEC EDGAR